Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026
Amylyx Pharmaceuticals reported interim safety data from the Phase 1 LUMINA trial of AMX0114 in ALS, showing no drug-related serious adverse events in the lowest dose cohort. Biomarker levels, including neurofilament light, remained near baseline, supporting the decision to continue evaluating the drug at higher dose levels.
Key figures
- Drug Name
- AMX0114
- Phase Of Trial
- Phase 1
- Total cohorts
- 4
- Cohort 1 dose mg
- 12.5
- Cohort 2 dose mg
- 25
- Cohort 3 dose mg
- 50
- Dosing frequency
- once every four weeks
- Target enrollment
- 48
- Randomization ratio
- 3:1
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.